Literature DB >> 28738008

Randomized placebo-controlled study of the effects of Yunnan Baiyao on hemostasis in horses.

SallyAnne L Ness, Amelia H Frye, Thomas J Divers, Mark Rishniw, Hollis N Erb, Marjory B Brooks.   

Abstract

OBJECTIVE To determine effects of oral administration of Yunnan Baiyao on platelet activation, coagulation, and fibrinolysis in healthy horses. ANIMALS 12 healthy adult horses. PROCEDURES In a randomized blinded crossover study that included a 4-week washout period between treatments, horses were orally administered a paste containing Yunnan Baiyao (15 mg/kg) or placebo at 12-hour intervals for 3 days. Blood samples were collected before start of treatment (time 0) and at 24 and 72 hours for a CBC, measurement of fibrinogen concentration, coagulation screening tests, and a panel of assays to assess platelet activation (including ADP- and collagen-induced aggregation and closure times, flow-cytometric variables of platelet-leukocyte aggregates, platelet membrane P-selectin and phosphatidylserine expression, and microparticle release), von Willebrand factor (vWF) concentration, and cofactor activity. In addition, thrombelastography was used to evaluate fibrin formation in tissue factor-activated whole blood and plasma and to assess tissue plasminogen activator-induced plasma fibrinolysis. For each treatment, values obtained before and 72 hours after start of administration were compared by use of Wilcoxon signed rank tests. RESULTS Yunnan Baiyao treatment had no significant effect on any hemostatic variable, compared with results for the placebo treatment. CONCLUSIONS AND CLINICAL RELEVANCE Administration of Yunnan Baiyao at a dosage typically used in clinical practice had no effect on in vitro measures of platelet or vWF function and no enhancement of fibrin-clot formation or stability. Any hemostatic actions of Yunnan Baiyao may require higher dosages or result from cell-surface interactions at sites of vascular and tissue injury not examined in this study.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28738008     DOI: 10.2460/ajvr.78.8.969

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  UPLC-G2Si-HDMS Untargeted Metabolomics for Identification of Yunnan Baiyao's Metabolic Target in Promoting Blood Circulation and Removing Blood Stasis.

Authors:  Qingyu Zhang; Aihua Zhang; Fangfang Wu; Xijun Wang
Journal:  Molecules       Date:  2022-05-17       Impact factor: 4.927

Review 2.  Research Advances in Pharmacology, Safety, and Clinical Applications of Yunnan Baiyao, a Traditional Chinese Medicine Formula.

Authors:  Qi Yao; Bo-Tao Chang; Rong Chen; Yi-Jing Wei; Qiu-Ju Gong; Dan Yu; Yang Zhang; Xu Han; Hong-Bo Yang; Song-Jiang Tang; Ying Gao
Journal:  Front Pharmacol       Date:  2021-11-24       Impact factor: 5.810

3.  A UPLC-MS-based metabolomics approach to reveal the attenuation mechanism of Caowu compatibility with Yunnan Baiyao.

Authors:  Jun-Ling Ren; Hui Sun; Hui Dong; Le Yang; Ai-Hua Zhang; Ying Han; Li Wang; Liang Liu; Xi-Jun Wang
Journal:  RSC Adv       Date:  2019-03-18       Impact factor: 4.036

Review 4.  Chinmedomics, a new strategy for evaluating the therapeutic efficacy of herbal medicines.

Authors:  Ying Han; Hui Sun; Aihua Zhang; Guangli Yan; Xi-Jun Wang
Journal:  Pharmacol Ther       Date:  2020-09-18       Impact factor: 12.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.